Multiplexed CRISPR technologies for gene editing and transcriptional regulation.

McCarty NS, Graham AE, Studená L, Ledesma-Amaro R. · 2020

Read Multiplexed CRISPR technologies for gene editing and transcriptional regulation. by McCarty NS, Graham AE, Studená L, Ledesma-Amaro R. (2020) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc7062760.txt.

Introduction

McCarty and co-authors review multiplexed CRISPR technologies in Nature Communications. Multiplexing runs many guide RNAs or several Cas enzymes at once, so many genes can be edited or tuned together. Native bacterial CRISPR systems already work this way, storing memories of past infections in arrays. Engineers have borrowed that architecture for far more ambitious tasks.

The review explains how to assemble, express, and process synthetic guide RNA arrays inside living cells. Applications that gain from multiplexing include cellular recorders that log events in DNA, genetic circuits, biosensors, and large-scale screens that perturb gene combinations. Metabolic pathways can be rewired wholesale rather than one step at a time. The authors also flag emerging challenges, such as cross-talk between enzymes, and the design care future studies need. Multiplexing, they argue, is what turns CRISPR from a scalpel into a programming language for cells.

Catalog record

CREATORMcCarty NS, Graham AE, Studená L, Ledesma-Amaro R.
YEAR2020
COLLECTIONPAPERS
FORMATTXT
FILE SIZE81 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC7062760

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Multiplexed CRISPR technologies for gene editing and transcriptional regulation By Nicholas S McCarty, Alicia E Graham, Lucie Studená, Rodrigo Ledesma-Amaro Published in: Nature Communications DOI: 10.1038/s41467-020-15053-x ABSTRACT Abstract Multiplexed CRISPR technologies, in which numerous gRNAs or Cas enzymes are expressed at once, have facilitated powerful biological engineering applications, vastly enhancing the scope and efficiencies of genetic editing and transcriptional regulation. In this review, we discuss multiplexed CRISPR technologies and describe methods for the assembly, expression and processing of synthetic guide RNA arrays in vivo. Applications that benefit from multiplexed CRISPR technologies, including cellular recorders, genetic circuits, biosensors, combinatorial genetic perturbations, large-scale genome engineering and the rewiring of metabolic pathways, are highlighted. We also offer a glimpse of emerging challenges and emphasize experimental considerations for future studies. Subject terms: Genetic engineering, Gene expression, Synthetic biology INTRODUCTION Most archaea and about half of bacteria carry the genes necessary for CRISPR–Cas adaptive immunity, which provides a memory of prior infections by encoding short DNA sequences into CRISPR (clustered regularly interspaced short palindromic repeats) loci within their genome. These prior infections are stored as spacer sequences, each of which is flanked by repeat sequences. Spacer repeats are transcribed into pre-crRNA (CRISPR RNAs), which are then processed into functional crRNAs1. Native CRISPR–Cas systems are inherently multiplexed; organisms can encode one or several CRISPR arrays and express numerous Cas (CRISPR-associated) proteins that facilitate the acquisition of new spacers and process the CRISPR arrays2. Over the last few years, thousands of studies have employed CRISPR–Cas technologies to edit, or transcriptionally regulate, individual genetic loci based on their sequence complementarity with designed guide RNAs (gRNAs). Despite the general utility of CRISPR–Cas technologies, the use of an individual gRNA limits efficiencies and biotechnological applications. Therefore, there is now a growing trend in studies that move away from mono-guide approaches, and instead use multiplexed strategies for multi-locus editing or transcriptional regulation. While only four PubMed papers mentioned “multiplex” and “CRISPR” in 2013, 81 such papers were published in 2018. CRISPR systems underpinning bacterial adaptive immunity function thanks to an intricate dance between CRISPR arrays and multiple Cas enzymes; the core of this review advocates for a return to this “natural state” and emphasizes the advantages of expressing multiple Cas proteins or gRNAs simultaneously in vivo to edit or transcriptionally regulate numerous genetic loci in parallel. In this review, we highlight strategies to create and process synthetic gRNA arrays in a multitude of organisms, emphasize the utility of inducible and orthogonal CRISPR–Cas technologies, and discuss the plethora of applications made possible by parallel targeting of genes in vivo, including biosensing, large-scale genome engineering, the construction of logic circuits, and metabolic engineering. We also argue for an enhanced focus on rigorous, quantitative experiments to fully validate and study gRNA functions in vivo, and describe the suite of computational tools available to design gRNAs. Finally, we conclude with outstanding challenges and future scientific directions ripe for innovation in the CRISPR multiplexing field. CRISPR FOR GENE EDITING AND TRANSCRIPTIONAL REGULATION While many Cas proteins have been discovered, Cas9 and Cas12a (also known as Cpf1), which are RNA-guided endonucleases that cleave target DNA, are the most commonly used for genetic editing and transcriptional regulation3. Cas9 and Cas12a are remarkably simple to program and can be directed to DNA targets via Watson-Crick base pairing between the genetic target and gRNA. In native CRISPR systems, gRNAs for Cas9 are comprised of a crRNA:tracrRNA complex, which can be fused together via genetic engineering to form a sgRNA (single gRNA), while those for Cas12a consist solely of a crRNA3,4. To avoid confusion throughout this review, we use the term ‘gRNA’ to represent all CRISPR gRNA formats4. After forming a ribonucleoprotein complex with a gRNA, Cas9 and Cas12a perform a double-strand break adjacent to a protospacer adjacent motif (PAM), a sequence that is required for target recognition and varies between endonucleases4. This double-strand break enables genome editing applications. By mutating specific amino acids in Cas9 and Cas12a, DNA cleavage activity in these enzymes is abolished, thus converting them into nuclease-null mutants, denoted as dCas9 and dCas12a5. Fusion of dCas enzymes to effector domains enables efficient transcriptional regulation, including CRISPR-mediated inhibition (CRISPRi) and activation (CRISPRa)5,6. Mechanistically, dCas enzymes repress transcription by preventing the binding of RNA polymerase or, if targeted to open reading frames, by interfering with transcription elongation5,7. In eukaryotes, dCas is typically fused to an effector domain to enhance repression by recruiting chromatin remodeling proteins while, in bacteria, dCas enzymes alone are usually sufficient to repress gene expression by physically blocking RNA polymerase5,6,8. Similarly, effector domains for CRISPRa work by recruiting RNA polymerase or by recruiting endogenous transcriptional activators6,7,9–13. Both CRISPR-based gene editing and transcriptional regulation benefit from multiplexing (Fig. 1). By producing multiple gRNAs and a Cas protein in vivo, researchers can build layered genetic circuits that control cellular behavior or modulate metabolic pathways with the simultaneous editing, activation, and downregulation of multiple target genes14–17. For gene editing, CRISPRa and CRISPRi, the targeting of multiple gRNAs to a single genetic locus also enhances the efficiency of DNA editing and transcriptional control18–20. [Figure: Basic overview of multiplexed CRISPR–Cas technologies.Multiplexed CRISPR–Cas can be implemented by simultaneously expressing multiple gRNAs at once. By adding orthologous Cas enzymes, gene editing, transcriptional activation (CRISPRa) and transcriptional repression (CRISPRi) can be performed in tandem at numerous locations in the genome. Cas enzymes are represented by the shaded green shape, while green and red cylinders attached to the Cas enzymes represent activation and repression domains, respectively. Editing requires that a Cas enzyme cleave dsDNA, which is repaired by error-prone, non-homologous end joining. Transcriptional regulation occurs by targeting nuclease-null Cas enzymes to specific regions up- or downstream of a transcription start site to either occlude RNA polymerase binding sites, or to recruit transcription factors (via fused effector domains) for activation or repression of the target gene.] Importantly, many methods to express and process multiplexed gRNAs in vivo are based on crRNA-processing mechanisms found in native CRISPR systems. To process CRISPR arrays, some native systems rely on the nuclease itself (e.g., Cas12a and Cas13a), some rely on accessory proteins that are part of the final effector complex (e.g., Cas6/Csy4 as part of Cascade), and others rely upon a combination of tracrRNA (transactivating crRNA) and RNase III (e.g., Cas9, Cas12b, and Cas12c)21. TRANSCRIPTION AND PROCESSING OF GRNA ARRAYS While a simple approach to target multiple genetic loci at once in vivo is to simply transfect cells with preformed ribonucleoprotein complexes, many applications (discussed in the following sections) demand sustained functionality of CRISPR–Cas over time. Fortunately, in recent years, many strategies to genetically encode, transcribe and process large numbers of gRNAs in vivo have been developed. There are three main “genetic architectures” for multiplexed gRNA expression. In both eukaryotes and bacteria, multiple gRNAs can be expressed by encoding each under the control of an individual promoter (typically Pol III U6 promoters in mammalian cells and Pol III tRNA promoters in yeast and plants) and terminator (Fig. 2a). Pol III promoters are high fidelity, but have a lower processivity than Pol II promoters22. Both Pol II and Pol III promoters have been used to express gRNAs for CRISPR–Cas studies, but Pol II promoters are easily tuned and often inducible. [Figure:

Read the complete text